Here, we establish that anti-GARP:TGF-β1 mAbs do not require FcγR-dependent functions to exert anti-tumor activity in mice, supporting a mode of action by which they block TGF-β1 activation and downstream signaling without depleting GARP-expressing cells. The gene discussed is FCGR2A; the disease is neoplasm.